10-propargyl-10-deazaaminopterin and Diffuse Mixed Small and Large Cell Lymphoma

10-propargyl-10-deazaaminopterin has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Molina, JR	1
Duffull, SB; Fleisher, M; Hamlin, P; Horwitz, S; Mould, DR; Neylon, E; O'Connor, OA; Saunders, ME; Sirotnak, F; Sweeney, K	1
Gardner, J; Gonen, M; Heaney, M; O'Connor, OA; Sirotnak, F; Smith, EA; Teruya-Feldstein, J; Toner, LE; Vrhovac, R	1

Reviews

1 review(s) available for 10-propargyl-10-deazaaminopterin and Diffuse Mixed Small and Large Cell Lymphoma

Article	Year
Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies. IDrugs : the investigational drugs journal, 2008, Volume: 11, Issue:7 Topics: Aminopterin; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; Folic Acid Antagonists; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin	2008

Other Studies

2 other study(ies) available for 10-propargyl-10-deazaaminopterin and Diffuse Mixed Small and Large Cell Lymphoma

Article	Year
A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Clinical pharmacology and therapeutics, 2009, Volume: 86, Issue:2 Topics: Adult; Aged; Aminopterin; Antineoplastic Agents; Area Under Curve; Biomarkers; Body Size; Drug Administration Schedule; Female; Folic Acid Antagonists; Hodgkin Disease; Humans; Incidence; Lymphoma, Non-Hodgkin; Male; Methylmalonic Acid; Middle Aged; Models, Statistical; Mucositis; Predictive Value of Tests; Recurrence; Severity of Illness Index; Vitamin B 12	2009
The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Feb-01, Volume: 12, Issue:3 Pt 1 Topics: Aminopterin; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cytarabine; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Gemcitabine; Humans; In Vitro Techniques; Lymphoma, Non-Hodgkin; Methotrexate; Mice; Mice, SCID; Time Factors; Xenograft Model Antitumor Assays	2006

Article

Year

A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.

Clinical pharmacology and therapeutics, 2009, Volume: 86, Issue:2

Topics: Adult; Aged; Aminopterin; Antineoplastic Agents; Area Under Curve; Biomarkers; Body Size; Drug Administration Schedule; Female; Folic Acid Antagonists; Hodgkin Disease; Humans; Incidence; Lymphoma, Non-Hodgkin; Male; Methylmalonic Acid; Middle Aged; Models, Statistical; Mucositis; Predictive Value of Tests; Recurrence; Severity of Illness Index; Vitamin B 12

2009

The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Feb-01, Volume: 12, Issue:3 Pt 1

Topics: Aminopterin; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cytarabine; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Gemcitabine; Humans; In Vitro Techniques; Lymphoma, Non-Hodgkin; Methotrexate; Mice; Mice, SCID; Time Factors; Xenograft Model Antitumor Assays

2006